Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Haemato-oncology

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Eli Lilly’s Inluriyo approved by FDA for breast cancer

    The oral drug can be used to treat advanced or metastatic breast cancer

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links